Search PubMed⌕ Search

Biomedical subjects

H Dufour

Publications and source records attributed to H Dufour.

At least 145 records · Page 8Linked to original sources
PubMed1978

[Depressive inhibition].

Inhibition is a fundamental concept in the field of depression. It underlies the notion of restraint, and one may recognize in it motor, affective and psychic components. This symptom can be identified from behaviour and actual experiences. Its coexistence with other depression target-symptoms helps to differenciate several clinical forms. It is a preferential symptom, especially at the time of the switch process, for establishing correlations with other parameters, biological and neurophysiological, of depression.

Affective Symptoms↗
PubMed1977

[Alterations of sleep caused by acute and chronic adminstration of lithium].

The sleep of 2 groups of subjects receiving lithium was studied. Ten normal controls after 17 days of lithium had a significant decrease of Paradoxical Sleep duration, with an increase of PS latency. A second group of 10 manic-depressive patients had received lithium for 22 +/- 6 months when they were recorded. They had a greater amount of slow wave sleep than the control group before lithium but the difference of PS duration was only related to a first night effect. Therefore sleep changes induced by lithium are different according to the duration of lithium administration. In any case they are less important than those induced by most of the anti-depressants.

Adult↗
PubMed1976

[Metapramine: antidepressant and psycho-stimulant].

Metapramine is a new antidepressant drug. A tricyclic molecule gives it a novel activity in so far as its thymoanaleptic and, at the same time, psychostimulating actions are concerned. Quick acting, metapramine has a very interesting peculiarity: its large tolerance which seems to be related to a no-anticholinergic effect.

Adjustment Disorders↗
PubMed1976

[Amitriptyline in psychiatric therapeutics. Apropos of 8 years of its use in hospital practice].

A hundred and thirty patients have been treated with Amitriptylin in the "Clinique de Psychiatrie" in Marseille during the last eight years. The review of the hundred cases for which the information are the most detailed show that Amitriptylin remains one of the most powerful, manageable and well-tolerated anti-depressant drugs available at the present time. Its therapeutic indications are numerous, but the best ones are proceeding from depressed states with high anxious participation in subjects of less that 60 years of age.

Adjustment Disorders↗
PubMed1975

[A new substituted benzamide with neuroleptic effects: lin 14 18 or sultopride].

After the research about Sulpiride, a new substituted benzamide has been studied. Although it was characterized by modest pharmacological effects in the neuroleptic identification tests, LIN 1418 turned out to have very interesting therapeutic properties. A study conducted with 50 cases, 30 of which were submitted a systematic pluridisciplinary control, leads to provisory conclusions as follows: 1) its psychotropic effects are powerful and constant; 2) its prevailing action is antipsychotic and desinhibiting altogether; 3) while LIN 1418 appears as successful with all psychoses, whether acute or chronic, up to now, the quality of its results in many chronic psychoses seems to be particularly remarkable; 4) its side-effects are those of most neuroleptics: its extrapyramidal symptoms being all the more obvious as the patient's "passivity" is less important.

Adult↗